Antibodies
Assay Kits
Biology Cells
cDNA
Clia Kits
Culture Cells
Devices
DNA
DNA Templates
Elisa Kits
Enzymes
Equipments
Exosomes
Gels
Isotypes
Medium & Serums
NATtrol
Panel
Particles
PCR
Pcr Kits
Peptides
Reagents
Recombinant Proteins
Ria Kits
RNA
Test Kits
Vector & Virus
Western Blot
Mu-driven transposition of recombinant mini-Mu unit DNA
Mu-driven transposition of recombinant mini-Mu unit DNA within the Corynebacterium glutamicum chromosome.
A dual-component Mu-transposition system was modified for the mixing/amplification of genes in Corynebacterium. The system consists of two varieties of plasmids: (i) a non-replicative integrative plasmid that accommodates the transposing mini-Mu(LR) unit bracketed by the L/R Mu ends or the mini-Mu(LER) unit, which moreover accommodates the enhancer component, E, and (ii) an integration helper plasmid that expresses the transposition issue genes for MuA and MuB.
Environment friendly transposition within the C. glutamicum chromosome (≈ 2 × 10-Four per cell) occurred primarily by the replicative pathway by way of cointegrate formation adopted by doable decision. Optimizing the E location within the mini-Mu unit considerably elevated the effectivity of Mu-driven intramolecular transposition-amplification in C. glutamicum in addition to in gram-negative micro organism.
The brand new C. glutamicum genome modification technique that was developed permits the resultant unbiased integration/amplification/fixation of goal genes at excessive copy numbers. After integration/amplification of the primary mini-Mu(LER) unit within the C. glutamicum chromosome, the E-element, which is bracketed by lox-like websites, is excised by Cre-mediated vogue, thereby fixing the truncated mini-Mu(LR) unit in its place for the following integration/ amplification of recent mini-Mu(LER) models. This technique was demonstrated utilizing the genes for the citrine and inexperienced fluorescent proteins, yECitrine and yEGFP, respectively.
Mouse anti VEGFR-3/Flt-4 (#1) (human) |
|||
101-M36 | Angio Proteomie | 100ug | EUR 297.6 |
Mouse anti VEGFR-1/Flt-1-Biotin (#EWF) (human) |
|||
101-MBi28 | Angio Proteomie | 50ug | EUR 297.6 |
VEGFR-1 / FLT-1 Antibody |
|||
abx239393-100ug | Abbexa | 100 ug | EUR 577.2 |
VEGFR-1/FLT-1 antibody |
|||
E39-09393 | EnoGene | 100ug/100ul | EUR 225 |
Description: Available in various conjugation types. |
VEGFR-1/FLT-1 antibody |
|||
CAF50629-100ug | Biomatik Corporation | 100ug | EUR 312 |
Anti-Mouse VEGFR-1/Flt-1 Antibody |
|||
103-M31 | ReliaTech | 100 µg | EUR 399 |
Description: Vascular Endothelial Growth Factor (VEGF or VEGF-A) family members are major mediators of vasculogenesis and angiogenesis. Specifically, biological activities attributed to VEGFs include: mitogenic activity on endothelial cells, increased permeability of endothelial cells to proteins, stimulation of monocyte migration across endothelial cells and angiogenic activity. Three VEGF family receptors have been described: Flt-1 (fms-like tyrosine kinase) also known as VEGF R1, KDR (kinase-insert domain-containing receptor) also known as Flk-1 and VEGF R2, and Flt-4 also known as VEGF R3. The three receptors contain seven extracellular immunoglobulin-like domains and share substantial sequence homology. In addition, neuropilin-1, a neuronal receptor, also acts as a co-receptor for VEGF when expressed on vascular endothelial cells, endothelial cell progenitors and monocytes. VEGF R1 is expressed primarily on endothelial cells but is also found on human peripheral blood monocytes. Through its endothelial mitogenic and hyperpermeability activities, VEGF influences a variety of immune functions related to wound healing and blood protein traffic across endothelial barriers. |
Mouse anti VEGFR-3/Flt-4-Biotin (#1) (human) |
|||
101-MBi36 | Angio Proteomie | 50ug | EUR 297.6 |
Recombinant Human FLT-1/VEGFR-1 Protein |
|||
RP01137 | Abclonal | 50μg | EUR 308.75 |
Rabbit anti VEGFR-3/Flt-4 (human) |
|||
102-PA22AG | Angio Proteomie | 50ug | EUR 240 |
Rabbit anti VEGFR-3/Flt-4 (human) |
|||
102-PA22S | Angio Proteomie | 100ug | EUR 240 |
Anti-Human VEGFR-1/Flt-1 (Peptide), soluble Antibody |
|||
102-PA21S | ReliaTech | 100 µg | EUR 126 |
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. |
Rabbit Anti-Human VEGFR-1 Flt-1 (Peptide), soluble |
|||
102-PA21 | Angio Proteomie | 100ug | EUR 240 |
Active Recombinant Human FLT-1/VEGFR-1 Protein |
|||
RP01188 | Abclonal | 5 μg | EUR 32.5 |
Human FLT-1/VEGFR-1 Control/blocking peptide #1 |
|||
FLT11-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Anti-Hu/Mo VEGFR-1/Flt-1, Antagonistic Antibody |
|||
mV1004.1m-h-m | ReliaTech | 100 µg | EUR 645.75 |
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The antibody will bind near the ligand binding site of the receptor and has antagonistic activity by blocking the binding of natural ligands. |
Biotinylated Recombinant Human FLT-1/VEGFR-1 Protein |
|||
RP02100 | Abclonal | 500μg | EUR 2843.75 |
Rabbit Anti-human FLT-1/VEGFR-1 IgG #1, aff pure |
|||
FLT11-A | Alpha Diagnostics | 100 ul | EUR 578.4 |
Human VEGFR-1/Flt-1 (D5), soluble Recombinant Protein |
|||
S01-011 | ReliaTech | 5 µg | EUR 73.5 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-5 (sVEGFR-1(D5)) is a 70 kDa protein. The baculovirus generated, recombinant human sVEGFR-1 is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 5 extracellular domains, which contain all the information necessary for high affinity ligand binding. The receptor monomers have a mass of approximately 70 kDa. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor. |
Human VEGFR-1/Flt-1 (D5), soluble Recombinant Protein |
|||
S01-012 | ReliaTech | 20 µg | EUR 157.5 |
Description: Recombinat human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-5 (sVEGFR-1(D5)) is a 70 kDa protein containing amino acid residues. The baculovirus generated, recombinant human sVEGFR-1 is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 5 extracellular domains, which contain all the information necessary for high affinity ligand binding. The receptor monomers have a mass of approximately 70 kDa. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVE supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor. |
Human VEGFR-1/Flt-1 (D4), soluble Recombinant Protein |
|||
S01-013 | ReliaTech | 5 µg | EUR 103.95 |
Description: Recombinant Human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-4 (sVEGFR-1(D4)) is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 4 extracellular domains, which contain all the information necessary for binding of VEGF. The receptor monomers have a mass of approximately 55 kDa containing 457 amino acid residues. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor. |
Human VEGFR-1/Flt-1 (D4), soluble Recombinant Protein |
|||
S01-014 | ReliaTech | 20 µg | EUR 199.5 |
Description: Recombinant Human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-4 (sVEGFR-1(D4)) is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 4 extracellular domains, which contain all the information necessary for binding of VEGF. The receptor monomers have a mass of approximately 55 kDa containing 457 amino acid residues. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor. |
Human VEGFR-1/Flt-1 (D3), soluble Recombinant Protein |
|||
S01-015 | ReliaTech | 5 µg | EUR 103.95 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-3 (sVEGFR-1(D3)) is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 3 extracellular domains, which contain all the information necessary for binding of VEGF. The receptor monomers have a mass of approximately 45 kDa containing 352 amino acid residues. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor. |
Human VEGFR-1/Flt-1 (D3), soluble Recombinant Protein |
|||
S01-016 | ReliaTech | 20 µg | EUR 199.5 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-3 (sVEGFR-1(D3)) is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 3 extracellular domains, which contain all the information necessary for binding of VEGF. The receptor monomers have a mass of approximately 45 kDa containing 352 amino acid residues. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor. |
Human VEGFR-1/Flt-1 (native), soluble Recombinant Protein |
|||
S01-009 | ReliaTech | 5 µg | EUR 73.5 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1) is the naturally occurring form and was cloned from total RNA of human umbilical vein endothelial cells. The recombinant mature sVEGFR-1 is a glycosylated monomeric protein with a mass of approximately 96 kDa. The soluble receptor precursor protein consists of the first 6 extracellular domains (Met1-His688) containing the unique 31 amino acids residues at the C-terminus. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly, a naturally occurring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor. |
Human VEGFR-1/Flt-1 (native), soluble Recombinant Protein |
|||
S01-010 | ReliaTech | 20 µg | EUR 157.5 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1) is the naturally occurring form and was cloned from total RNA of human umbilical vein endothelial cells. The recombinant mature sVEGFR-1 is a glycosylated monomeric protein with a mass of approximately 96 kDa. The soluble receptor protein consists of the first 6 extracellular domains (Met1-His688) containing the unique 31 amino acids residues at the C-terminus. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly, a naturally occurring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis binding VEGF with the same affinity as the full-length receptor. |
Anti-Human VEGFR-3/FLT-4 Antibody |
|||
101-M37 | ReliaTech | 100 µg | EUR 199.5 |
Description: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk 1) and VEGFR-3 (FLT-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. These receptors play essential roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The VEGFR-3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR-3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGF R3 (Flt-4). The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stage of development. It is important for lymphangiogenesis. |
Anti-Human VEGFR-3/FLT-4 Antibody |
|||
101-M38 | ReliaTech | 100 µg | EUR 399 |
Description: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (Flt1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides which remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system. |
Anti-Human VEGFR-3/FLT-4 Antibody |
|||
101-M870 | ReliaTech | 100 µg | EUR 399 |
Description: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (Flt1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides which remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system. |
Anti-Human VEGFR-3/FLT-4 Antibody |
|||
102-PA22 | ReliaTech | 200 µg | EUR 147 |
Description: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelia cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system. |
Anti-Human VEGFR-3/FLT-4 Antibody |
|||
102-PABi22 | ReliaTech | 50 µg | EUR 157.5 |
Description: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelia cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system. |
Human VEGFR-1/Flt-1 (D3)-His, soluble Recombinant Protein |
|||
S01-080 | ReliaTech | 50 µg | EUR 378 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 domain D1-3 (sVEGFR-1(D3)) is produced as a non-chimeric protein in a monomeric form. The soluble receptor protein contains only the first 3 extracellular domains, which contain all the information necessary for binding of VEGF. The receptor monomers have a mass of approximately 45 kDa containing 352 amino acid residues. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor. |
Mouse Monoclonal Anti-human FLT-1/VEGFR-1 IgG, aff pure |
|||
FLT12-M | Alpha Diagnostics | 100 ug | EUR 578.4 |
Mouse Monoclonal Anti-human FLT-1/VEGFR-1 IgG, aff pure |
|||
FLT14-M | Alpha Diagnostics | 100 ug | EUR 578.4 |
VEGFR-3/Flt-4 |
|||
JP27779 | Demeditec Diagnostics | 96 | EUR 611 |
Anti-Mouse VEGFR-3/FLT-4 Antibody |
|||
103-M36 | ReliaTech | 100 µg | EUR 246.75 |
Description: VEGFR-3, also known as FLT4, is a member of the Tyr protein kinase family. The extracellular portion of VEGFR-3 contains 7 immunoglobulin (Ig)-like domains and the cytoplasmic portion contains a protein kinase domain. FLT4 regulates angiogenesis and lymphangiogenesis, its ligands are VEGF-C and D and its binding is mediated by the 2nd and 3rd Ig-like domains of FLT4. During fetal development VEGFR-3 is expressed on endothelial cells, however, in the adult mice, the vascular endothelial cells lose VEGFR-3 expression, but the lymphatic endothelium expresses it constitutively. In addition, VEGFR-3 expression can be induced in tumors with active angiogenesis. |
Anti-Mouse VEGFR-3/FLT-4 Antibody |
|||
103-M38 | ReliaTech | 100 µg | EUR 399 |
Description: Receptor tyrosine kinase VEGFR-3, also known as Flt-4, together with VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remaining linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system. |
Human VEGFR-3 / Flt-4 GENLISA ELISA |
|||
KBH0215 | Krishgen | 1 x 96 wells | EUR 286 |
Human VEGFR-1/Flt-1(D7)-Fc Chimera, soluble Recombinant Protein |
|||
SFC-005 | ReliaTech | 10 µg | EUR 57.75 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1(D7)) was fused with the Fc part of human IgG1. The recombinant mature sVEGFR-1(D7)/Fc is a disulfide-linked homodimeric protein. The sVEGFR-1(D7)/Fc monomers have a mass of approximately 130 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Thr751), which contain all the information necessary for high affinity ligand binding. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signalling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation. Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occurring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. |
Human VEGFR-1/Flt-1(D7)-Fc Chimera, soluble Recombinant Protein |
|||
SFC-006 | ReliaTech | 50 µg | EUR 168 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1(D7)) was fused with the Fc part of human IgG1. The recombinant mature sVEGFR-1(D7)/Fc is a disulfide-linked homodimeric protein. The sVEGFR-1(D7)/Fc monomers have a mass of approximately 130 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Thr751), which contain all the information necessary for high affinity ligand binding. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signalling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation. Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occurring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. |
Rabbit Anti-Mouse FLT-1/VEGFR-1 (279-299aa) IgG, aff pure |
|||
FLT15-A | Alpha Diagnostics | 100 ul | EUR 578.4 |
Human VEGFR-3/FLT-4/Fc Chimera, soluble |
|||
SFC-010 | Angio Proteomie | 50ug | EUR 378 |
Rabbit Anti-Mouse FLT-4/VEGFR-3 IgG #1, aff pure |
|||
FLT41-A | Alpha Diagnostics | 100 ug | EUR 578.4 |
Active Recombinant Human VEGFR-3/FLT-4 Protein |
|||
RP00123 | Abclonal | 10 μg | EUR 175.5 |
Human VEGFR-3/FLT-4, soluble Recombinant Protein |
|||
S01-017 | ReliaTech | 10 µg | EUR 103.95 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-3 (sVEGFR-3/FLT-4) was fused with a carboxy-terminal 6X histidine-tag. The recombinant mature sVEGFR-3/FLT-4 is a glycosylated monomeric protein. The sVEGFR-3/FLT-4 monomers have a mass of approximately 120 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Glu774). All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751aa residue extracellular domain, a 22aa transmembrane domain and a 482aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. |
Human VEGFR-3/FLT-4, soluble Recombinant Protein |
|||
S01-017S | ReliaTech | 5 µg | EUR 63 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-3 (sVEGFR-3/FLT-4) was fused with a carboxy-terminal 6X histidine-tag. The recombinant mature sVEGFR-3/FLT-4 is a glycosylated monomeric protein. The sVEGFR-3/FLT-4 monomers have a mass of approximately 120 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Glu774). All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751aa residue extracellular domain, a 22aa transmembrane domain and a 482aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. |
Human VEGFR-3/FLT-4, soluble Recombinant Protein |
|||
S01-018 | ReliaTech | 50 µg | EUR 210 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-3 (sVEGFR-3/FLT-4) was fused with a carboxy-terminal 6X histidine-tag. The recombinant mature sVEGFR-3/FLT-4 is a glycosylated monomeric protein. The sVEGFR-3/FLT-4 monomers have a mass of approximately 120 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Glu774). All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The FLT-4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain and a 482aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis. |
FLT-1/VEGFR1 Human, Antibody |
|||
GWB-BE9645 | GenWay Biotech | 0.1 mg | Ask for price |
Rat Monoclonal anti-Mouse VEGFR-3 (FLT-4) Antibody |
|||
xAP-0836 | Angio Proteomie | 100ug | EUR 280 |
Mouse FLT-4/VEGFR-3 Control/blocking peptide #1 |
|||
FLT41-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Human FLT-4/VEGFR-3 control/blocking peptide #2 |
|||
FLT42-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Rabbit Anti-Human FLT-4/VEGFR-3 IgG #2, aff pure |
|||
FLT42-A | Alpha Diagnostics | 100 ug | EUR 578.4 |
Mouse VEGFR-1/Flt-1(D7)-Fc Chimera, soluble Recombinant Protein |
|||
SFC-M05 | ReliaTech | 10 µg | EUR 57.75 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1D1-7) was fused with the Fc part of human IgG1. The recombinant mature sVEGFR-1D1-7/Fc is a disulfide-linked homodimeric protein. The sVEGFR-1D1-7/Fc monomers have a mass of approximately 130 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Thr751), which contain all the information necessary for high affinity ligand binding. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signalling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation. Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occurring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. |
Mouse VEGFR-1/Flt-1(D7)-Fc Chimera, soluble Recombinant Protein |
|||
SFC-M06 | ReliaTech | 50 µg | EUR 168 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1D1-7) was fused with the Fc part of human IgG1. The recombinant mature sVEGFR-1D1-7/Fc is a disulfide-linked homodimeric protein. The sVEGFR-1D1-7/Fc monomers have a mass of approximately 130 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Thr751), which contain all the information necessary for high affinity ligand binding. Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation. Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 (sVEGFR-1). No naturally occurring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. |
Human VEGFR1/Flt-1 ELISA KIT |
|||
E42EH-249 | EnoGene | 96T/48T | Ask for price |
Human VEGFR-1/Flt1 ELISA Kit |
|||
EHV0045 | Abclonal | 96Tests | EUR 625.2 |
Human VEGFR-3/FLT-4/Fc Chimera, soluble Recombinant Protein |
|||
SFC-009 | ReliaTech | 10 µg | EUR 73.5 |
Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-3 (sVEGFR-3) was fused with the Fc part of human IgG1. The recombinant mature sVEGFR-3/Fc is a disulfide-linked homodimeric protein. The sVEGFR-3/Fc monomers have a mass of approximately 130 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Glu774). All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The VEGFR-3/FLT-4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751aa residue extracellular domain, a 22aa transmembrane domain and a 482aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The FLT-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial at latter stages of development. It is important for lymphangiogenesis. |
VEGFR-1/Flt1/ Rat VEGFR- 1/ Flt1 ELISA Kit |
|||
ELA-E0147r | Lifescience Market | 96 Tests | EUR 1063.2 |
Anti-VEGFR-1/FLT-1 antibody |
|||
PAab09393 | Lifescience Market | 100 ug | EUR 426 |
FLT-1/ VEGFR1 AB1 |
|||
GWB-91AE5A | GenWay Biotech | 0.5 ml | Ask for price |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC040659-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF405S conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC040659-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF405S conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/658) Antibody |
|||
BNC810658-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF680R conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/658) Antibody |
|||
BNC810658-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF680R conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC810659-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF680R conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC810659-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF680R conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC940659-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF594 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC940659-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF594 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC880659-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF488A conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC880659-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF488A conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/658) Antibody |
|||
BNC800658-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF680 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/658) Antibody |
|||
BNC800658-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF680 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC800659-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF680 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC800659-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF680 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/658) Antibody |
|||
BNC430658-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF543 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/658) Antibody |
|||
BNC430658-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF543 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC430659-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF543 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC430659-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF543 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC400659-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF640R conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC400659-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF640R conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/658) Antibody |
|||
BNC050658-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF405M conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/658) Antibody |
|||
BNC050658-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF405M conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC050659-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF405M conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC050659-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF405M conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC470659-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF647 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC470659-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF647 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/658) Antibody |
|||
BNC550658-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF555 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/658) Antibody |
|||
BNC550658-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/658), CF555 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC550659-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF555 conjugate, Concentration: 0.1mg/mL |
VEGFR1 / Flt-1(FLT1/659) Antibody |
|||
BNC550659-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF555 conjugate, Concentration: 0.1mg/mL |
Outcomes of cytomegalovirus DNA viral hundreds expressed in copies per millilitre and worldwide models per millilitre are equal.
Quantification of Cytomegalovirus (CMV) DNA is required for the initiation and monitoring of anti-viral remedy and the detection of viral resistance. Nonetheless, because of the lack of standardisation of CMV DNA nucleic acid checks, it’s troublesome to set common thresholds. In 2010, the 1st WHO Worldwide Normal for Human Cytomegalovirus for Nucleic Acid Amplification Strategies was launched. Since then CMV DNA viral load assays have been calibrated utilizing this normal.
Three exterior high quality evaluation (EQA) suppliers despatched the identical 5 samples to their contributors and analysed the outcomes to find out the equivalence of reporting CMV DNA leads to worldwide models per millilitre (IU/mL), and in contrast the distinction in outcomes reported in IU/mL with these reported in copies per millilitre (c/mL), and to find out the speed of adoption of IU/mL. About 78% of contributors proceed to report leads to c/mL although six of the 12 industrial assays are calibrated towards the usual.
The vary of the outcomes reported in IU/mL was lower than these reported in c/mL indicating that the adoption of the WHO normal efficiently improved the reporting of the CMV viral load.
The variation in particular person pattern outcomes reported by completely different assays, no matter whether or not in IU/mL or c/mL, continues to be nice and subsequently extra standardisation of the assays is required to permit the setting of remedy and monitoring thresholds. This research can act as a bench mark to find out price of future adoption if reporting CMV DNA viral load leads to IU/mL.
S1 satellite tv for pc DNA repetitive models show equivalent construction and total variability in all Anatolian brown frog taxa.
S1 satellite tv for pc DNA from Palearctic brown frogs has a species-specific construction in all European species. We characterised S1 satellite tv for pc DNA from the Anatolian brown frogs Rana macrocnemis, R. camerani, and R. holtzi as a way to outline their taxonomic rank and the construction of this satellite tv for pc on this frog lineage. Southern blots of genomic DNA digested with KpnI, EcoRV, NdeI, NheI, or StuI produced the identical sample of satellite tv for pc DNA bands. Furthermore, quantitative dot blots confirmed that this satellite tv for pc DNA accounts for 0.1 % of the genome in all taxa.
- Evaluation of the general genomic variability of the S1a repeat sequence in specimens from numerous populations demonstrated that this repetitive unit additionally has the identical dimension (476 bp), the identical most typical sequence (MCS) and the identical total variability in all three taxa, and in addition in R. macrocnemis tavasensis.
- The S1a repetitive unit presents three deletions of 9, eight and 1 bp in comparison with the 494-bp S1a repeat from European frogs. The S1a MCS has three variable positions (sequence WWTK in positions 183-186), because of the presence of two repeat subpopulations with motifs AATG and WWTT in all taxa. In contrast to beforehand analyzed mitochondrial and nuclear sequences that present appreciable variations amongst these taxa, no distinction could possibly be detected within the construction and variability of the S1 satellite tv for pc repetitive models.
- This implies that these taxa ought to belong to a single species. Our outcomes point out that this satellite tv for pc DNA selection most likely shaped when the Anatolian lineage radiated from widespread ancestor about Four mya, and since then has maintained its construction in all 4 taxa examined.
Human CellExp? DKK-1, Human Recombinant |
|||
7132-10 | Biovision | each | EUR 333.6 |
Human CellExp? DKK-1, Human Recombinant |
|||
7132-50 | Biovision | each | EUR 1358.4 |
DKK-1 (HEK293-expressed), Human |
|||
HY-P7155A | MedChemExpress | 50ug | EUR 1011.6 |
human Dkk-1 Recombinant Protein |
|||
100-407 | ReliaTech | 10 µg | EUR 196.35 |
Description: DKK-1 is a member of the DKK protein family which also includes DKK-2, DKK-3 and DKK-4. DKK-1 was originally identified as a Xenopus head forming molecule that behaves as an antagonist for Wnt signaling. Subsequent studies have shown that DKK-1 and DKK-4 play an important regulatory role in the Wnt /β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/βcatenin signaling system. LPR5 and LPR6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/βcatenin signaling cascade. It has been suggested that by inhibiting Wnt/β-catenin signaling, which is essential for posterior patterning in vertebrates, DKK-1 permits anterior development. This notion is supported by the finding that mice deficient of DKK-1 expression lack head formation and die during embryogenesis. Recombinant human DKK-1 expressed in human 293 cells is a 35-40 kDa glycoprotein containing 235 amino-acid residues. |
human Dkk-1 Recombinant Protein |
|||
100-407S | ReliaTech | 2 µg | EUR 92.4 |
Description: DKK-1 is a member of the DKK protein family which also includes DKK-2, DKK-3 and DKK-4. DKK-1 was originally identified as a Xenopus head forming molecule that behaves as an antagonist for Wnt signaling. Subsequent studies have shown that DKK-1 and DKK-4 play an important regulatory role in the Wnt /β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/βcatenin signaling system. LPR5 and LPR6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/βcatenin signaling cascade. It has been suggested that by inhibiting Wnt/β-catenin signaling, which is essential for posterior patterning in vertebrates, DKK-1 permits anterior development. This notion is supported by the finding that mice deficient of DKK-1 expression lack head formation and die during embryogenesis. Recombinant human DKK-1 expressed in human 293 cells is a 35-40 kDa glycoprotein containing 235 amino-acid residues. |
Human Dkk-1 Recombinant Protein |
|||
200-013 | ReliaTech | 20 µg | EUR 136.5 |
Description: DKK-1 is a member of the DKK protein family which also includes DKK-2, DKK-3 and DKK-4. DKK-1 was originally identified as a Xenopus head forming molecule that behaves as an antagonist for Wnt signaling. Subsequent studies have shown that DKK-1 and DKK-4 play an important regulatory role in the Wnt /β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/βcatenin signaling system. LPR5 and LPR6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/βcatenin signaling cascade. It has been suggested that by inhibiting Wnt/β-catenin signaling, which is essential for posterior patterning in vertebrates, DKK-1 permits anterior development. This notion is supported by the finding that mice deficient of DKK-1 expression lack head formation and die during embryogenesis. Recombinant human DKK-1 fused to a C terminal His-tag derived from E. coli is a 26 kDa protein containing 235 amino-acid residues. |
Human Dkk-1 Recombinant Protein |
|||
200-013S | ReliaTech | 5 µg | EUR 92.4 |
Description: DKK-1 is a member of the DKK protein family which also includes DKK-2, DKK-3 and DKK-4. DKK-1 was originally identified as a Xenopus head forming molecule that behaves as an antagonist for Wnt signaling. Subsequent studies have shown that DKK-1 and DKK-4 play an important regulatory role in the Wnt /β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/βcatenin signaling system. LPR5 and LPR6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/βcatenin signaling cascade. It has been suggested that by inhibiting Wnt/β-catenin signaling, which is essential for posterior patterning in vertebrates, DKK-1 permits anterior development. This notion is supported by the finding that mice deficient of DKK-1 expression lack head formation and die during embryogenesis. Recombinant human DKK-1 fused to a C terminal His-tag derived from E. coli is a 26 kDa protein containing 235 amino-acid residues. |
Recombinant Human DKK-1 Protein |
|||
PROTO94907-3 | BosterBio | 10ug | EUR 380.4 |
Description: DKK-1 is a member of the DKK protein family which also includes DKK-2, DKK-3 and DKK-4. DKK-1 was originally identified as a Xenopus head forming molecule that behaves as an antagonist for Wnt signaling. Subsequent studies have shown that DKK-1 and DKK-4 play an important regulatory role in the Wnt /β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/βcatenin signaling system. LPR5 and LPR6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/βcatenin signaling cascade. It has been suggested that by inhibiting Wnt/β-catenin signaling, which is essential for posterior patterning in vertebrates, DKK-1 permits anterior development. This notion is supported by the finding that mice deficient of DKK-1 expression lack head formation and die during embryogenesis. Recombinant human DKK-1 expressed in human 293 cells is a 35-40 kDa glycoprotein containing 235 amino-acid residues. |
Dkk-1 |
|||
GT30000 | Neuromics | 50 ug | EUR 631.2 |
Human DKK Antibody |
|||
E63C02401 | EnoGene | 100ug/100ul | EUR 225 |
Description: Available in various conjugation types. |
Human DKK-1 PicoKine ELISA Kit |
|||
EK0867 | BosterBio | 96 wells | EUR 510 |
Description: For quantitative detection of human DKK1 in cell culture supernates, cell lysates, serum and plasma (heparin, EDTA). |
Active Recombinant Human Dkk-1 Protein |
|||
RP01343 | Abclonal | 100μg | EUR 162.5 |
Human DKK-1 Recombinant Protein Lyophilized |
|||
IHUDKK1RLY2UG | Innovative research | each | EUR 341 |
Description: Human DKK-1 Recombinant Protein Lyophilized |
Human DKK-1 ELISA kit (4×96T) |
|||
LF-EK50798 | Abfrontier | 4×96T | EUR 2641.2 |
Nori® Human DKK-1 ELISA Kit |
|||
GR106268 | Genorise Scientific | 96-well | EUR 461 |
DKK-1 Antibody |
|||
F51803-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 322.15 |
Description: DKK-1 is a protein that is a member of the dickkopf family. It is a secreted protein with two cysteine rich regions and is involved in embryonic development through its inhibition of the WNT signaling pathway. Elevated levels of DKK-1 in bone marrow plasma and peripheral blood is associated with the presence of osteolytic bone lesions in patients with multiple myeloma. |
OKRC00363-96W - Dkk-1 ELISA Kit (Human) |
|||
OKRC00363-96W | Aviva Systems Biology | 96Wells | EUR 525 |
OKAG00221-96W - Dkk-1 ELISA Kit (Human) |
|||
OKAG00221-96W | Aviva Systems Biology | 1plate:12x8-WellMicrostrips | EUR 475 |
Human DKK Antibody-HRP |
|||
E63C02402 | EnoGene | 100ug/100ul | EUR 275 |
Description: Available in various conjugation types. |
DKK-3 ELISA KIT|Human |
|||
EF000091 | Lifescience Market | 96 Tests | EUR 826.8 |
Human DKK Antibody-BIOTIN |
|||
E63C02403 | EnoGene | 100ug/100ul | EUR 275 |
Description: Available in various conjugation types. |
Recombinant Human DKK1/Dkk-1 Protein (His Tag) |
|||
PKSH033697-10ug | Elabscience Biotech | 10ug | EUR 178 |
Description: Human |
Recombinant Human DKK1/Dkk-1 Protein (His Tag) |
|||
PKSH033697-50ug | Elabscience Biotech | 50ug | EUR 523 |
Description: Human |
human Dkk-3 Recombinant Protein |
|||
100-408 | ReliaTech | 10 µg | EUR 196.35 |
Description: The dickkopf (DKK)-related protein family is comprised of four central members, DKK-1 - 4, along with the distantly-related DKK family member DKK-l1 (Soggy), which is thought to be a descendent of an ancestral DKK-3 precursor due to its unique sequence homology to DKK-3 and no other DKK family member. DKK family members, with the exception of the divergent Soggy, share two conserved cysteine-rich domains and show very little sequence similarity outside of these domains. Playing an important regulatory role in vertebrate development through localized inhibition of Wnt regulated processes, including anterior-posterior axial patterning, limb development, somitogenesis, and eye formation, DKKs have also been implicated post-developmentally in bone formation, bone disease, cancer, and neurodegenerative diseases. DKK proteins typically play an important regulatory role in the Wnt /β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/β-catenin signaling system. LRP5 and LRP6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/β-catenin signaling cascade. DKK-3 has been shown to potentiate, rather than inhibit, Wnt signaling through interactions with the high-affinity, transmembrane coreceptors Kremen-1 (Krm1) and Kremen-2 (Krm2). Recombinant human DKK-3 expressed in CHO cells is a glycoprotein that has a calculated molecular weight of 36.3 kDa and contains 329 amino acid residues. Due to glycosylation, human DKK-3 migrates at an apparent molecular weight of approximately 39-49 kDa by SDS-PAGE analysis under non-reducing conditions. |
human Dkk-3 Recombinant Protein |
|||
100-408S | ReliaTech | 2 µg | EUR 92.4 |
Description: The dickkopf (DKK)-related protein family is comprised of four central members, DKK-1 - 4, along with the distantly-related DKK family member DKK-l1 (Soggy), which is thought to be a descendent of an ancestral DKK-3 precursor due to its unique sequence homology to DKK-3 and no other DKK family member. DKK family members, with the exception of the divergent Soggy, share two conserved cysteine-rich domains and show very little sequence similarity outside of these domains. Playing an important regulatory role in vertebrate development through localized inhibition of Wnt regulated processes, including anterior-posterior axial patterning, limb development, somitogenesis, and eye formation, DKKs have also been implicated post-developmentally in bone formation, bone disease, cancer, and neurodegenerative diseases. DKK proteins typically play an important regulatory role in the Wnt /β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/β-catenin signaling system. LRP5 and LRP6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/β-catenin signaling cascade. DKK-3 has been shown to potentiate, rather than inhibit, Wnt signaling through interactions with the high-affinity, transmembrane coreceptors Kremen-1 (Krm1) and Kremen-2 (Krm2). Recombinant human DKK-3 expressed in CHO cells is a glycoprotein that has a calculated molecular weight of 36.3 kDa and contains 329 amino acid residues. Due to glycosylation, human DKK-3 migrates at an apparent molecular weight of approximately 39-49 kDa by SDS-PAGE analysis under non-reducing conditions. |
human Dkk-2 Recombinant Protein |
|||
100-436 | ReliaTech | 10 µg | EUR 196.35 |
Description: The dickkopf (DKK)-related protein family is comprised of four central members, DKK-1 - 4, along with the distantly-related DKK family member DKK-11 (Soggy), which is thought to be a descendent of an ancestral DKK-3 precursor due to its unique sequence homology to DKK-3 and no other DKK family member. DKK family members, with the exception of the divergent Soggy, share two conserved cysteine-rich domains and show very little sequence similarity outside of these domains. Playing an important regulatory role in vertebrate development through localized inhibition of Wnt-regulated processes, including anterior-posterior axial patterning, limb development, somitogenesis, and eye formation, DKKs have also been implicated post-developmentally in bone formation, bone disease, cancer, and neurodegenerative diseases. DKK proteins typically play an important regulatory role in the Wnt/β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/β-catenin signaling system. LRP5 and LRP6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/β-catenin signaling cascade. DKK-2 has been shown to both inhibit and enhance canonical Wnt signaling; enhancing Wnt signaling through direct high-affinity binding of DKK-2 to LRP6 during LRP6 overexpression, while inhibiting Wnt signaling and promoting LRP6 internalization through the formation of a ternary complex between DKK-2, LRP6, and Kremen-2. Recombinant Human DKK-2 expressed in CHO cells is a glycoprotein that has a calculated molecular weight of 25.8 kDa and contains 234 amino acid residues. Due to glycosylation, human DKK-2 migrates at an apparent molecular weight of approximately 31-36 kDa by SDS-PAGE analysis under non-reducing conditions. |
human Dkk-2 Recombinant Protein |
|||
100-436S | ReliaTech | 2 µg | EUR 92.4 |
Description: The dickkopf (DKK)-related protein family is comprised of four central members, DKK-1 - 4, along with the distantly-related DKK family member DKK-11 (Soggy), which is thought to be a descendent of an ancestral DKK-3 precursor due to its unique sequence homology to DKK-3 and no other DKK family member. DKK family members, with the exception of the divergent Soggy, share two conserved cysteine-rich domains and show very little sequence similarity outside of these domains. Playing an important regulatory role in vertebrate development through localized inhibition of Wnt-regulated processes, including anterior-posterior axial patterning, limb development, somitogenesis, and eye formation, DKKs have also been implicated post-developmentally in bone formation, bone disease, cancer, and neurodegenerative diseases. DKK proteins typically play an important regulatory role in the Wnt/β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/β-catenin signaling system. LRP5 and LRP6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/β-catenin signaling cascade. DKK-2 has been shown to both inhibit and enhance canonical Wnt signaling; enhancing Wnt signaling through direct high-affinity binding of DKK-2 to LRP6 during LRP6 overexpression, while inhibiting Wnt signaling and promoting LRP6 internalization through the formation of a ternary complex between DKK-2, LRP6, and Kremen-2. Recombinant Human DKK-2 expressed in CHO cells is a glycoprotein that has a calculated molecular weight of 25.8 kDa and contains 234 amino acid residues. Due to glycosylation, human DKK-2 migrates at an apparent molecular weight of approximately 31-36 kDa by SDS-PAGE analysis under non-reducing conditions. |
Human Dkk-2 Recombinant Protein |
|||
200-014 | ReliaTech | 20 µg | EUR 136.5 |
Description: The dickkopf (DKK)-related protein family is comprised of four central members, DKK-1 - 4, along with the distantly-related DKK family member DKK-11 (Soggy), which is thought to be a descendent of an ancestral DKK-3 precursor due to its unique sequence homology to DKK-3 and no other DKK family member. DKK family members, with the exception of the divergent Soggy, share two conserved cysteine-rich domains and show very little sequence similarity outside of these domains. Playing an important regulatory role in vertebrate development through localized inhibition of Wnt-regulated processes, including anterior-posterior axial patterning, limb development, somitogenesis, and eye formation, DKKs have also been implicated post-developmentally in bone formation, bone disease, cancer, and neurodegenerative diseases. DKK proteins typically play an important regulatory role in the Wnt/β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/β-catenin signaling system. LRP5 and LRP6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/β-catenin signaling cascade. DKK-2 has been shown to both inhibit and enhance canonical Wnt signaling; enhancing Wnt signaling through direct high-affinity binding of DKK-2 to LRP6 during LRP6 overexpression, while inhibiting Wnt signaling and promoting LRP6 internalization through the formation of a ternary complex between DKK-2, LRP6, and Kremen-2. Recombinant Human DKK-2 fused to a C terminal His-tag derived from E. coli has a molecular weight of 26.0 kDa and contains 234 amino acid residues. |
Human Dkk-2 Recombinant Protein |
|||
200-014S | ReliaTech | 5 µg | EUR 92.4 |
Description: The dickkopf (DKK)-related protein family is comprised of four central members, DKK-1 - 4, along with the distantly-related DKK family member DKK-11 (Soggy), which is thought to be a descendent of an ancestral DKK-3 precursor due to its unique sequence homology to DKK-3 and no other DKK family member. DKK family members, with the exception of the divergent Soggy, share two conserved cysteine-rich domains and show very little sequence similarity outside of these domains. Playing an important regulatory role in vertebrate development through localized inhibition of Wnt-regulated processes, including anterior-posterior axial patterning, limb development, somitogenesis, and eye formation, DKKs have also been implicated post-developmentally in bone formation, bone disease, cancer, and neurodegenerative diseases. DKK proteins typically play an important regulatory role in the Wnt/β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/β-catenin signaling system. LRP5 and LRP6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/β-catenin signaling cascade. DKK-2 has been shown to both inhibit and enhance canonical Wnt signaling; enhancing Wnt signaling through direct high-affinity binding of DKK-2 to LRP6 during LRP6 overexpression, while inhibiting Wnt signaling and promoting LRP6 internalization through the formation of a ternary complex between DKK-2, LRP6, and Kremen-2. Recombinant Human DKK-2 fused to a C terminal His-tag derived from E. coli has a molecular weight of 26.0 kDa and contains 234 amino acid residues. |
Recombinant Human Dkk-3 Protein |
|||
RP00209 | Abclonal | 10 μg | EUR 97.5 |
Recombinant Human Dkk-3 Protein |
|||
RP00355 | Abclonal | 10 μg | EUR 196.8 |
Anti-Human Dkk-1 Antibody |
|||
102-PA33 | ReliaTech | 200 µg | EUR 204.75 |
Description: DKK-1 is a member of the DKK protein family which also includes DKK-2, DKK-3 and DKK-4. DKK-1 was originally identified as a Xenopus head forming molecule that behaves as an antagonist for Wnt signaling. Subsequent studies have shown that DKK-1 and DKK-4 play an important regulatory role in the Wnt /β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/βcatenin signaling system. LPR5 and LPR6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/βcatenin signaling cascade. It has been suggested that by inhibiting Wnt/β-catenin signaling, which is essential for posterior patterning in vertebrates, DKK-1 permits anterior development. This notion is supported by the finding that mice deficient of DKK-1 expression lack head formation and die during embryogenesis. Recombinant human DKK-1 fused to a C terminal His-tag derived from E. coli is a 26 kDa protein containing 235 amino-acid residues. |
Anti-Human Dkk-1 Antibody |
|||
102-PA33S | ReliaTech | 100 µg | EUR 126 |
Description: DKK-1 is a member of the DKK protein family which also includes DKK-2, DKK-3 and DKK-4. DKK-1 was originally identified as a Xenopus head forming molecule that behaves as an antagonist for Wnt signaling. Subsequent studies have shown that DKK-1 and DKK-4 play an important regulatory role in the Wnt /β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/βcatenin signaling system. LPR5 and LPR6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/βcatenin signaling cascade. It has been suggested that by inhibiting Wnt/β-catenin signaling, which is essential for posterior patterning in vertebrates, DKK-1 permits anterior development. This notion is supported by the finding that mice deficient of DKK-1 expression lack head formation and die during embryogenesis. Recombinant human DKK-1 fused to a C terminal His-tag derived from E. coli is a 26 kDa protein containing 235 amino-acid residues. |
Anti-Human Dkk-1 Antibody |
|||
101-M380 | ReliaTech | 100 µg | EUR 399 |
Description: Dkk1 is a Dickkopf-related protein that inhibits Wnt signaling by binding the Wnt coreceptor LRP5/6. It also binds Kremen1 and Kremen2. Dkk1 is important in embryonic development. |
Anti-Human Dkk-1 Antibody |
|||
101-M426 | ReliaTech | 100 µg | EUR 399 |
Description: Dkk1 is a Dickkopf-related protein that inhibits Wnt signaling by binding the Wnt coreceptor LRP5/6. It also binds Kremen1 and Kremen2. Dkk1 is important in embryonic development. |
Human Dkk-1 Protein, Fc Tag (MALS verified) |
|||
DK1-H5258 | ACROBIOSYSTEMS | 1mg | EUR 310.3 |
Description: Human Dkk-1, Fc Tag (DK1-H5258) is expressed from human 293 cells (HEK293). It contains AA Thr 32 - His 266 (Accession # NP_036374.1). |
Dkk-1 ELISA Kit (Human) : 96 Wells (OKAG00221) |
|||
OKAG00221 | Aviva Systems Biology | 96 Wells | EUR 715.2 |
Description: Description of target: This gene encodes a protein that is a member of the dickkopf family. It is a secreted protein with two cysteine rich regions and is involved in embryonic development through its inhibition of the WNT signaling pathway. Elevated levels of DKK1 in bone marrow plasma and peripheral blood is associated with the presence of osteolytic bone lesions in patients with multiple myeloma.;Species reactivity: Human;Application: ELISA;Assay info: Quantitative Colorimentric Sandwich ELISA;Sensitivity: 63 pg/mL |
Human Dkk-1 Protein, His Tag, premium grade |
|||
DK1-H5221 | ACROBIOSYSTEMS | 1mg | EUR 139.1 |
Description: Human Dkk-1 Protein, His Tag, premium grade (DK1-H5221) is expressed from human 293 cells (HEK293). It contains AA Thr 32 - His 266 (Accession # NP_036374.1). |
Biotinylated Human Dkk-1 Protein, Fc,Avitag™ |
|||
DK1-H82F5 | ACROBIOSYSTEMS | 25ug | EUR 1487.3 |
Description: Biotinylated Human Dkk-1, Fc,Avitag (DK1-H82F5) is expressed from human 293 cells (HEK293). It contains AA Thr 32 - His 266 (Accession # O94907-1). |
Human DKK-1(Dickkopf-related protein 1) ELISA Kit |
|||
EH0113 | FN Test | 96T | EUR 628.92 |
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 18.75pg/ml |
Human DKK-1(Dickkopf-related protein 1) ELISA Kit |
|||
EKF57029-48T | Biomatik Corporation | 48T | EUR 396.9 |
Human DKK-1(Dickkopf-related protein 1) ELISA Kit |
|||
EKF57029-5x96T | Biomatik Corporation | 5x96T | EUR 2693.25 |
Human DKK-1(Dickkopf-related protein 1) ELISA Kit |
|||
EKF57029-96T | Biomatik Corporation | 96T | EUR 567 |
Rabbit Anti Human DKK PcAb |
|||
E61C02403 | EnoGene | 100ug | EUR 225 |
Description: Available in various conjugation types. |
Rabbit Anti Human DKK PcAb |
|||
E61C02403a | EnoGene | 1mg | EUR 1125 |
Description: Available in various conjugation types. |
Dkk-1 Rabbit pAb |
|||
E2251891 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
Recombinant Human DKK-1/DKK1 Protein, 8* His Tag |
|||
E40KMH986 | EnoGene | 20ug | EUR 495 |
Human DKK-2 Protein, His Tag |
|||
DK2-H5323 | ACROBIOSYSTEMS | 1mg | EUR 224.7 |
Description: Human DKK-2 Protein, His Tag (DK2-H5323) is expressed from CHO cells. It contains AA Lys 34 - Ile 259 (Accession # Q9UBU2). |
Recombinant Human DKK1/Dkk-1 Protein (His Tag)(Active) |
|||
PKSH031807-100ug | Elabscience Biotech | 100ug | EUR 636 |
Description: Human |
Recombinant Human DKK1/Dkk-1 Protein (His Tag)(Active) |
|||
PKSH031807-20ug | Elabscience Biotech | 20ug | EUR 303 |
Description: Human |
Human DKK-4 PicoKine ELISA Kit |
|||
EK0868 | BosterBio | 96 wells | EUR 546 |
Description: For Quantitative Detection of human DKK-4 in cell culture supernates, serum and plasma(heparin, EDTA). |
Human DKK-3 PicoKine ELISA Kit |
|||
EK1323 | BosterBio | 96 wells | EUR 510 |
Description: For quantitative detection of human DKK-3 in cell culture supernates, cell lysates, serum and plasma (heparin, EDTA). |
Dkk-1 Polyclonal Antibody |
|||
41928-100ul | SAB | 100ul | EUR 302.4 |
Dkk-1 Polyclonal Antibody |
|||
41928-50ul | SAB | 50ul | EUR 224.4 |
DKK-1 Recombinant Protein |
|||
40-225-0002mg | ProSci | 0.002 mg | EUR 311.1 |
Description: DKK-1 is a member of the DKK protein family which also includes DKK-2, DKK-3 and DKK-4. DKK-1 was originally identified as a Xenopus head forming molecule that behaves as an antagonist for Wnt signaling. Subsequent studies have shown that DKK-1 and DKK-4 play an important regulatory role in the Wnt /β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/βcatenin signaling system. LPR5 and LPR6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/βcatenin signaling cascade. It has been suggested that by inhibiting Wnt/β-catenin signaling, which is essential for posterior patterning in vertebrates, DKK-1 permits anterior development. This notion is supported by the finding that mice deficient of DKK-1 expression lack head formation and die during embryogenesis. Recombinant human DKK-1 expressed in human 293 cells is a 35-40 kDa glycoprotein containing 235 amino-acid residues. |
DKK-1 Recombinant Protein |
|||
40-225-001mg | ProSci | 0.01 mg | EUR 437.1 |
Description: DKK-1 is a member of the DKK protein family which also includes DKK-2, DKK-3 and DKK-4. DKK-1 was originally identified as a Xenopus head forming molecule that behaves as an antagonist for Wnt signaling. Subsequent studies have shown that DKK-1 and DKK-4 play an important regulatory role in the Wnt /β-catenin signaling pathway by forming inhibitory complexes with LDL receptor-related proteins 5 and 6 (LRP5 and LRP6), which are essential components of the Wnt/βcatenin signaling system. LPR5 and LPR6 are single-pass transmembrane proteins that appear to act as co-receptors for Wnt ligands involved in the Wnt/βcatenin signaling cascade. It has been suggested that by inhibiting Wnt/β-catenin signaling, which is essential for posterior patterning in vertebrates, DKK-1 permits anterior development. This notion is supported by the finding that mice deficient of DKK-1 expression lack head formation and die during embryogenesis. Recombinant human DKK-1 expressed in human 293 cells is a 35-40 kDa glycoprotein containing 235 amino-acid residues. |
Dkk-1 Polyclonal Antibody |
|||
E041928 | EnoGene | 100μg/100μl | EUR 255 |
Description: Available in various conjugation types. |
Dkk-1 Polyclonal Antibody |
|||
E20-75562 | EnoGene | 100ug | EUR 225 |
Description: Available in various conjugation types. |
Dkk-1 Polyclonal Antibody |
|||
ABP53293-003ml | Abbkine | 0.03ml | EUR 189.6 |
Description: A polyclonal antibody for detection of Dkk-1 from Human, Mouse, Rat. This Dkk-1 antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Dkk-1 |
Dkk-1 Polyclonal Antibody |
|||
ABP53293-01ml | Abbkine | 0.1ml | EUR 346.8 |
Description: A polyclonal antibody for detection of Dkk-1 from Human, Mouse, Rat. This Dkk-1 antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Dkk-1 |
Dkk-1 Polyclonal Antibody |
|||
ABP53293-02ml | Abbkine | 0.2ml | EUR 496.8 |
Description: A polyclonal antibody for detection of Dkk-1 from Human, Mouse, Rat. This Dkk-1 antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Dkk-1 |
Dkk-1 Recombinant Protein |
|||
96-861 | ProSci | 0.1 mg | EUR 651.3 |
Description: Members of the dickkopf-related protein family (DKK-1, -2, -3, and -4) are secreted proteins with two cysteine-rich domains separated by a linker region. And DKK1 takes part in embryonic development through its inhibition of the WNT signaling pathway, binds to LRP6 with high affinity and prevents the Frizzled-Wnt-LRP6 complex formation in response to Wnts. DKK1 promotes LRP6 internalization and degradation when it forms a ternary complex with the cell surface receptor Kremen.DKK1 not olny functions as a head inducer during development, but also regulates joint remodeling and bone formation, which suggests roles for DKK1 in the pathogenesis of rheumatoid arthritis and multiple myeloma. More recently research reported, DKK1 impacts eye development from a defined developmental time point on, and is critical for lens separation from the surface ectoderm via beta-catenin mediated Pdgfralpha and E-cadherin expression. |
Dkk-1 Recombinant Protein |
|||
96-990 | ProSci | 0.05 mg | EUR 714.3 |
Description: Members of the dickkopf-related protein family (DKK-1, -2, -3, and -4) are secreted proteins with two cysteine-rich domains separated by a linker region. And DKK1 takes part in embryonic development through its inhibition of the WNT signaling pathway, binds to LRP6 with high affinity and prevents the Frizzled-Wnt-LRP6 complex formation in response to Wnts. DKK1 promotes LRP6 internalization and degradation when it forms a ternary complex with the cell surface receptor Kremen.DKK1 not olny functions as a head inducer during development, but also regulates joint remodeling and bone formation, which suggests roles for DKK1 in the pathogenesis of rheumatoid arthritis and multiple myeloma. More recently research reported, DKK1 impacts eye development from a defined developmental time point on, and is critical for lens separation from the surface ectoderm via beta-catenin mediated Pdgfralpha and E-cadherin expression. |
Dkk-1 Polyclonal Antibody |
|||
E44H07004 | EnoGene | 100ul | EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
DKK-3 ELISA Kit (Human) (OKBB00603) |
|||
OKBB00603 | Aviva Systems Biology | 96 Wells | EUR 606 |
Description: Description of target: Dickkopf-related protein 3 is a protein that in humans is encoded by the DKK3 gene. This gene encodes a protein that is a member of the dickkopf family. It is mapped to 11p15.3. The secreted protein contains two cysteine rich regions and is involved in embryonic development through its interactions with the Wnt signaling pathway. The expression of this gene is decreased in a variety of cancer cell lines and it may function as a tumor suppressor gene. Members of the Dkk-related family display unique patterns of mRNA expression in human and mouse tissues, and are secreted when expressed in 293T cells. DKKs play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer disease.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich Immunoassay;Sensitivity: <= 10 pg/mL |
Nori® Human DKK-1 ELISA Kit (2 plates) |
|||
GR106268-2 | Genorise Scientific | 2 x 96-well | EUR 832 |
Dkk-2 |
|||
GT15222 | Neuromics | 100 ug | EUR 631.2 |
Human DKK-2 Recombinant Protein Lyophilized |
|||
IHUDKK2RLY2UG | Innovative research | each | EUR 317 |
Description: Human DKK-2 Recombinant Protein Lyophilized |
Human DKK-3 Recombinant Protein Lyophilized |
|||
IHUDKK3RLY2UG | Innovative research | each | EUR 317 |
Description: Human DKK-3 Recombinant Protein Lyophilized |
Mouse Monoclonal anti-human Dkk-1 |
|||
hAP-0246 | Angio Proteomie | 100ug | EUR 250 |
Mouse Monoclonal anti-human Dkk-1 |
|||
hAP-0246A | Angio Proteomie | 100ug | EUR 250 |
Sheep Polyclonal anti-Human Dkk-1 |
|||
hAP-5846 | Angio Proteomie | 50ug | EUR 400 |
Biotinylated Recombinant Human Dkk-3 Protein |
|||
RP02554 | Abclonal | 100μg | EUR 1423.5 |
Recombinant Human Dickkopf-Related Protein 1/DKK-1 (C-Fc) |
|||
PKSH034024-10ug | Elabscience Biotech | 10ug | EUR 100 |
Description: Human |
Recombinant Human Dickkopf-Related Protein 1/DKK-1 (C-Fc) |
|||
PKSH034024-50ug | Elabscience Biotech | 50ug | EUR 300 |
Description: Human |
Human Dkk-3 (R335G) Protein, His Tag |
|||
DK3-H5220 | ACROBIOSYSTEMS | 20ug | EUR 460.1 |
Description: Human Dkk-3 (R335G), His Tag (DK3-H5220) is expressed from human 293 cells (HEK293). It contains AA Ala 22 - Ile 350 (Accession # Q9UBP4-1 (R335G)). |
DKK 1 Recombinant Protein |
|||
96-236 | ProSci | 0.1 mg | EUR 752.1 |
Description: Members of the dickkopf-related protein family (DKK-1, -2, -3, and -4) are secreted proteins with two cysteine-rich domains separated by a linker region. And DKK1 takes part in embryonic development through its inhibition of the WNT signaling pathway, binds to LRP6 with high affinity and prevents the Frizzled-Wnt-LRP6 complex formation in response to Wnts. DKK1 promotes LRP6 internalization and degradation when it forms a ternary complex with the cell surface receptor Kremen.DKK1 not olny functions as a head inducer during development, but also regulates joint remodeling and bone formation, which suggests roles for DKK1 in the pathogenesis of rheumatoid arthritis and multiple myeloma. More recently research reported, DKK1 impacts eye development from a defined developmental time point on, and is critical for lens separation from the surface ectoderm via β-catenin mediated Pdgfrα and E-cadherin expression. |
DKK 1 Recombinant Protein |
|||
96-237 | ProSci | 0.025 mg | EUR 619.8 |
Description: Members of the dickkopf-related protein family (DKK-1, -2, -3, and -4) are secreted proteins with two cysteine-rich domains separated by a linker region. And DKK1 takes part in embryonic development through its inhibition of the WNT signaling pathway, binds to LRP6 with high affinity and prevents the Frizzled-Wnt-LRP6 complex formation in response to Wnts. DKK1 promotes LRP6 internalization and degradation when it forms a ternary complex with the cell surface receptor Kremen.DKK1 not olny functions as a head inducer during development, but also regulates joint remodeling and bone formation, which suggests roles for DKK1 in the pathogenesis of rheumatoid arthritis and multiple myeloma. More recently research reported, DKK1 impacts eye development from a defined developmental time point on, and is critical for lens separation from the surface ectoderm via β-catenin mediated Pdgfrα and E-cadherin expression. |
Rat DKK-1 ELISA Kit |
|||
EK5668 | SAB | 96 tests | EUR 599 |
Mouse Dkk-1 ELISA Kit |
|||
E28L0661 | EnoGene | 96T | EUR 666.67 |
Mouse Dkk-1 ELISA KIT |
|||
E42EM-173 | EnoGene | 96T/48T | Ask for price |
OKRC00364-96W - Dkk-3 ELISA Kit (Human) |
|||
OKRC00364-96W | Aviva Systems Biology | 96Wells | EUR 525 |
OKRC00365-96W - Dkk-4 ELISA Kit (Human) |
|||
OKRC00365-96W | Aviva Systems Biology | 96Wells | EUR 525 |
OKBB00603-96W - DKK-3 ELISA Kit (Human) |
|||
OKBB00603-96W | Aviva Systems Biology | 96Wells | EUR 538 |
DKK-1 (CHO-expressed), Mouse |
|||
HY-P7154 | MedChemExpress | 50ug | EUR 914.4 |
Dkk-1 Rabbit Polyclonal Antibody |
|||
ES4292-100ul | ELK Biotech | 100ul | EUR 124 |
Description: A Rabbit Polyclonal antibody against Dkk-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
Dkk-1 Rabbit Polyclonal Antibody |
|||
ES4292-50ul | ELK Biotech | 50ul | EUR 74 |
Description: A Rabbit Polyclonal antibody against Dkk-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
Recombinant Human DKK-3/DKK3 Protein, His Tag |
|||
E40KMH988 | EnoGene | 20ug | EUR 495 |